A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa

NCT ID: NCT00134966

Last Updated: 2017-05-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

493 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-08-31

Study Completion Date

2007-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to achieve approval for the use of carbidopa/levodopa/entacapone in early Parkinson's disease (PD) by demonstrating that when used as initial levodopa therapy in early PD, carbidopa/levodopa/entacapone provides significantly greater symptomatic benefit than immediate release carbidopa/levodopa administered at the same levodopa dosage level of 100 mg three times a day (t.i.d.).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to achieve approval for the use of carbidopa/levodopa/entacapone in early Parkinson's disease (PD) by demonstrating that when used as initial levodopa therapy in early PD, carbidopa/levodopa/entacapone provides significantly greater symptomatic benefit than immediate release carbidopa/levodopa administered at the same levodopa dosage level 100 mg t.i.d.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type EXPERIMENTAL

capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)

Intervention Type DRUG

2

Group Type ACTIVE_COMPARATOR

capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Stalevo CELC200

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 30 to 80 years, inclusive, at time of Parkinson's disease diagnosis
* Idiopathic Parkinson's disease with at least 2 cardinal signs of disease: resting tremor, bradykinesia or rigidity
* Parkinson's disease impairment warranting treatment with a levodopa formulation according to the investigator's assessment

Exclusion Criteria

* History, signs or symptoms suggesting the diagnosis of atypical or secondary Parkinsonism due to drugs, metabolic disorders, encephalitis or other neurodegenerative diseases
* History of stereotaxic brain surgery for PD (e.g., pallidotomy, deep brain stimulation, tissue transplant)
* Diagnosis of Parkinson's disease for more than 5 years prior to Screening
* Previous use of levodopa in any formulation, entacapone or tolcapone for more than 30 days or anytime within 4 weeks (28 days) prior to baseline
* Use of a dopamine agonist within 4 weeks (28 days) prior to baseline
Minimum Eligible Age

30 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Novartis

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Barrow Neurology Clinics at St. Joseph's Hosptial & Medical Center

Phoenix, Arizona, United States

Site Status

Coastal Neurological Medical Group, Inc

La Jolla, California, United States

Site Status

Neurosearch, Inc.

Reseda, California, United States

Site Status

University of Florida Health Science Center

Jacksonville, Florida, United States

Site Status

Mayo Clinic

Jacksonville, Florida, United States

Site Status

USF Medical Clinic

Tampa, Florida, United States

Site Status

Springfield Neurology Associates, LLC

Springfield, Massachusetts, United States

Site Status

Clinical Neuroscience Center

Southfield, Michigan, United States

Site Status

Melbourne Internal Medicine Associates

Westlake, Ohio, United States

Site Status

Westmoreland Neurology Associates, Inc.

Greensburg, Pennsylvania, United States

Site Status

Lankenau Hospital

Wynnewood, Pennsylvania, United States

Site Status

NeuroHealth

Warwick, Rhode Island, United States

Site Status

Coastal Neurology, PA

Beaufort, South Carolina, United States

Site Status

Senior Adults Specialty Research

Austin, Texas, United States

Site Status

Baylor College of Medicine, Parkinson's Disease Center

Houston, Texas, United States

Site Status

Neurology Associates

San Marcos, Texas, United States

Site Status

Blue Ridge Research Center at Roanoke Neurological Center

Roanoke, Virginia, United States

Site Status

Heritage Medical Research Clinic

Calgary, Alberta, Canada

Site Status

Moncton, New Brunswick, Canada

Site Status

Eastern Health Care - Health Sciences Centre, Neurology Department

HSC Room 5317, 300 Prince Philip Drive, Saint John's, Newfoundland and Labrador, Canada

Site Status

Neurology Division, Health Science Center

Halifax, Nova Scotia, Canada

Site Status

Cape Breton Regional Hospital, Neurology Department

Sydney, Nova Scotia, Canada

Site Status

Grand River Hospital

Kitchener, Ontario, Canada

Site Status

London Health Sciences Center, University Hospital, Rm. A10-026

London, Ontario, Canada

Site Status

Centre for Movement Disorders

Markham, Ontario, Canada

Site Status

Parkinson's & Neurodegenerative Disorders Clinic

Ottawa, Ontario, Canada

Site Status

Ottawa Hospital, Civic Campus

Ottawa, Ontario, Canada

Site Status

Hiren Desai Medicine Professional Corporation

Windsor, Ontario, Canada

Site Status

Neuro Rive Sud

Greenfield Park, Quebec, Canada

Site Status

Montreal General Hospital

Montreal, Quebec, Canada

Site Status

Unite des Troubles du Mouvement Andre-Barbeau, CHUM-Hotel-Dieu

Montreal, Quebec, Canada

Site Status

Centre de Recjerche Clinique du CHUS

Sherbrooke, Quebec, Canada

Site Status

Dr. Felix Veloso Research

Regina, Saskatchewan, Canada

Site Status

Quebec Memory and Motor Skills Disorders Clinic

Québec, , Canada

Site Status

University of Saskatchewan, Royal University Hospital

Saskatoon, , Canada

Site Status

Neurologická klinika, Univerzita Palackého

I.P.Pavlova 6, Olomouc, Czechia

Site Status

FN-neurologická klinika

Alej Svobody 80, Plzeň, Czechia

Site Status

Neurologicka klinika

Katerinska 12, Praha 2, , Czechia

Site Status

FN-Nemocnice Pardubice

Kyjevska 44, Pardubice, , Czechia

Site Status

Rambam Medical Center

Haliya Hashniya 8, Haifa District, Israel

Site Status

Dep. Of Neurology (Bitan 38, EEG institute)

Dep. of Neurology, Zerifin, , Israel

Site Status

Belinson Campus, Jabotinsky st. Movement Disorder Unit

Petah Tikva, , Israel

Site Status

Sourasky Medical Center

Weitzman Saint Movement Disorder Clinic, Tel Aviv, , Israel

Site Status

Clinica Neurologica I - Azienda Ospedaliera-Universitaria Policlinico - Università di Catania

Via Santa Sofia 78, Catania, Italy

Site Status

"Dipartimento di Neuroscienze Oftalmologia e Genetica (DINOG)

Università Degli Studi Di Genova, Via de Toni 5, Genova, Italy

Site Status

Unità Operativa Complessa Neurologia - Policlinico Universitario "G. Martino"

Via Consolare Valeria, Messina, Italy

Site Status

Istituto Nazionale Neurologico "Carlo Besta"

Via Celoria 11, Milano, Italy

Site Status

Dipartimento di Neuroscienze-Sezione Neurologia Università degli Studi di Pisa- AO S. Chiara

Via Roma, 67, Pisa, Italy

Site Status

Dipartimento di Scienze Neurologiche Università degli Studi di Roma "La Sapienza" Roma I

Viale dell'Università 30, Roma, Italy

Site Status

Dipartimento di Neuroscienze-Università degli Studi di Torino

Via Cherasco 15, Torino, Italy

Site Status

A.O. Istituti Clinici di Perfezionamento-Unita'Operativa Centro Parkinson

Via Bignami 1, Milan, , Italy

Site Status

Samodzielny Publiczny Szpital Kliniczny Oddzial Kliniczny Neurologii i Epiletologii

Ul. Czerniakowska 231, Warszawa, , Poland

Site Status

Centrum Neurologii Klinicznej

Ul. Dwernickiego 8, Krakow, , Poland

Site Status

Klinika Neruologii Wieku Podeszlego

ul.Medykow 14, Katowice, , Poland

Site Status

Hospitais da Universidade de Coimbra (Serv. Neurologia)

Avenida Bissaya Barreto, Coimbra, , Portugal

Site Status

Hospital de Santa Maria (Serv. Neurologia)

Avenida Professor Egas Moniz, Lisbon, , Portugal

Site Status

Hospital de Santo António (Serv. Neurologia)

Largo Professor Abel Salazar, Porto, , Portugal

Site Status

Istanbul CAPA Medical School

Istanbul University CAPA Medical School, Dept. of Neurology, Istanbul, Turkey (Türkiye)

Site Status

Hacettepe Medical School, Department of Neurology

Hacettepe Universitesi Hastaneleri Norooji AD Sihhiye, Ankara, , Turkey (Türkiye)

Site Status

Dokuz Eylul Medical School, Department of Neurology

Noroloji Anabilim Dali Inciralti Izmir, Izmir, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada Czechia Israel Italy Poland Portugal Turkey (Türkiye)

References

Explore related publications, articles, or registry entries linked to this study.

Hauser RA, Panisset M, Abbruzzese G, Mancione L, Dronamraju N, Kakarieka A; FIRST-STEP Study Group. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. Mov Disord. 2009 Mar 15;24(4):541-50. doi: 10.1002/mds.22343.

Reference Type DERIVED
PMID: 19058133 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CELC200A2305

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Comparison of Dopamin Level in Idiopathic Parkinson's Patients
NCT06115538 ENROLLING_BY_INVITATION PHASE4